ACR Convergence 2025| Video: Rheuminations on Milestones & Ageism

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • Technology
      • Information Technology
      • Apps
    • QA/QI
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
      • Education & Training
    • Certification
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: infliximab

Thoughtful Pediatric Care: Pediatric Cases Require Special Considerations & Aggressive Treatment Plans

Thomas R. Collins  |  March 9, 2020

In Canada, five provinces will now reimburse patients with plaque psoriasis who use risankizumab. Also, Canada Health has approved apremilast for treating adults with plaque psoriasis and psoriatic arthritis…

Filed under:Conditions Tagged with:2019 ACR/ARP Annual Meetingpediatric arthritisPediatric RheumatologyPediatrics

A Combined Immunosuppressive Regimen for ILD MDA5-Positive Dermatomyositis

Arthritis & Rheumatology  |  February 27, 2020

Interstitial lung disease accompanied by anti-melanoma differentiation-associated gene 5 positive dermatomyositis is often rapidly progressive and associated with poor prognosis. In this study, a combined immunosuppressive regimen of high-dose glucocorticoids, tacrolimus and intravenous cyclophosphamide proved more effective than treatment with high-dose glucocorticoids and stepwise addition of an immunosuppressant in a historical control group.

Filed under:ConditionsMyositisResearch Rheum Tagged with:Arthritis & Rheumatologydermatomyositis (DM)ILDinterstitial lung disease (ILD)Research

Coding Corner Questions: Using NP/PA Services in Practice

From the College  |  February 13, 2020

Scenario 1: Direct Billing A 70-year-old female patient with rheumatoid arthritis in multiple joints and positive rheumatoid factor returns to the practice for her fourth infusion of infliximab with the nurse practitioner (NP). She reports no fevers, cough, dyspnea or concurrent illness. She rates the severity of her joint pain at 6 on a 10-point…

Filed under:Billing/CodingFrom the College Tagged with:Medicarenurse practitionerphysician assistant

Range of Insurance Issues Challenge Rheumatology

Thomas R. Collins  |  February 12, 2020

ACR representatives updated members on recent insurance issues…

Filed under:Uncategorized

Remembering Etanercept & the Advent of the Biologic Era

Robert S. Katz, MD  |  February 10, 2020

As a veteran rheumatologist, I remember the clinical trials of etanercept’s (Enbrel’s) efficacy. And when the drug was first approved in 1998, I participated in those clinical trials and realized the effectiveness was astonishing. It was easy to tell which patients were treated with etanercept vs. those who received placebo, even though both groups were…

Filed under:Biologics/DMARDsSpeak Out Rheum Tagged with:etanerceptSpeak Out Rheumatology

Coverage & Reimbursement Challenges: Updates from the ACR Insurance Subcommittee Chair

Chris Phillips, MD  |  February 7, 2020

The ACR Insurance Subcommittee is working to address specialty pharmacy requirements for in-office treatments, elimination of consultation codes and other coverage and reimbursement challenges.

Filed under:Billing/CodingInsuranceLegislation & Advocacy Tagged with:ACR Insurance Subcommittee (ISC)Consultation CodesDr. Chris Phillipsmodifier 25specialty drug acquisition

Biologic Spending & Price Trends

Arthritis & Rheumatology  |  January 28, 2020

Any given rheumatology patient who needs a biologic disease-modifying anti-rheumatic drug (DMARD) will spend $22,000–44,000 on their medication each year…

Filed under:Biologics/DMARDsDrug Updates Tagged with:adalimumabbiologic drugsDisease-modifying antirheumatic drugs (DMARDs)etanerceptinfliximab

Tips for Exploring Tough Topics with Teens with Rheumatic Disease

Susan Bernstein  |  January 17, 2020

ATLANTA—Managing teenage patients may present challenges for pediatric rheumatologists and rheumatology professionals not only because of their often complex, rare conditions, but because teenagers are, well, teenagers. Teens may experiment with sexual intercourse, alcohol use, tobacco or vaping e-cigarettes to fit in with their peers, even if these habits have serious health consequences, according to…

Filed under:Patient PerspectivePresident's Perspective Tagged with:2019 ACR/ARP Annual MeetingLGBTQPediatric Rheumatology

Case Report: Possible Overlapping Vasculitis & Ulcerative Colitis

Julia Jing-ou Tan, MD, Mohammad Bardi, MD, & Natasha Dehghan, MD  |  January 17, 2020

A 42-year-old man with a history of ulcerative colitis (UC), primary sclerosing cholangitis (PSC) and chronic sinusitis was referred to a rheumatologist to evaluate for a possible diagnosis of systemic vasculitis. This patient had developed new skin lesions, gingival hypertrophy and ulcerating tracheobronchitis, concerning for possible granulomatosis with polyangiitis (GPA). Since 1994, the patient had…

Filed under:ConditionsVasculitis Tagged with:case reportulcerative colitis

RA Patients May Be Less Likely to Discontinue Etanercept Than Other TNF Inhibitors

Lara C. Pullen, PhD  |  January 8, 2020

In a systematic literature review, researchers found that rheumatoid arthritis patients taking etanercept were less likely to discontinue their treatment than patients using any of five other tumor necrosis factor inhibitors…

Filed under:ConditionsRheumatoid Arthritis Tagged with:etanerceptRheumatoid Arthritis (RA)TNF inhibitors

  • « Previous Page
  • 1
  • …
  • 12
  • 13
  • 14
  • 15
  • 16
  • …
  • 41
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences